$CRTG
CORETEC GROUP INC.

2023 Q3 Form 10-Q Financial Statement

#000143774923023164 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $310.0K $305.8K
YoY Change 2.99% -30.2%
% of Gross Profit
Research & Development $101.1K $121.4K
YoY Change 26.1% -0.34%
% of Gross Profit
Depreciation & Amortization $30.00K $23.04K
YoY Change 31.23% 1.14%
% of Gross Profit
Operating Expenses $101.1K $121.4K
YoY Change 26.1% -0.34%
Operating Profit
YoY Change
Interest Expense $54.49K $52.85K
YoY Change 3.14% 11.38%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$460.0K -$474.3K
YoY Change 6.56% -21.86%
Income Tax
% Of Pretax Income
Net Earnings -$456.6K -$474.3K
YoY Change 5.78% -21.86%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 284.1M 282.5M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.020M $1.450M
YoY Change -63.26% -53.29%
Cash & Equivalents $1.020M $1.450M
Short-Term Investments
Other Short-Term Assets $190.0K $31.48K
YoY Change 46.47% -55.95%
Inventory
Prepaid Expenses $185.7K $31.48K
Receivables
Other Receivables
Total Short-Term Assets $1.206M $1.481M
YoY Change -58.5% -53.35%
LONG-TERM ASSETS
Property, Plant & Equipment $110.8K $110.1K
YoY Change 46.09% 54.93%
Goodwill $166.0K $166.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $4.550K
YoY Change -100.0% 0.0%
Total Long-Term Assets $1.126M $1.146M
YoY Change -4.06% -3.66%
TOTAL ASSETS
Total Short-Term Assets $1.206M $1.481M
Total Long-Term Assets $1.126M $1.146M
Total Assets $2.332M $2.628M
YoY Change -42.83% -39.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $310.0K $314.4K
YoY Change 2.29% -29.05%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $360.0K $0.00
YoY Change 293.44%
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $671.7K $314.4K
YoY Change 70.23% -29.06%
LONG-TERM LIABILITIES
Long-Term Debt $1.245M $1.447M
YoY Change -10.97% 18.94%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.245M $1.447M
YoY Change -10.97% 18.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $671.7K $314.4K
Total Long-Term Liabilities $1.245M $1.447M
Total Liabilities $1.917M $1.762M
YoY Change 6.9% 6.13%
SHAREHOLDERS EQUITY
Retained Earnings -$17.78M -$17.33M
YoY Change 17.0% 17.33%
Common Stock $56.82K $56.63K
YoY Change 10.44% 10.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $415.5K $866.0K
YoY Change
Total Liabilities & Shareholders Equity $2.332M $2.628M
YoY Change -42.83% -39.81%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$456.6K -$474.3K
YoY Change 5.78% -21.86%
Depreciation, Depletion And Amortization $30.00K $23.04K
YoY Change 31.23% 1.14%
Cash From Operating Activities -$410.0K -$422.5K
YoY Change -14.74% 8.46%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $41.37K
YoY Change -243.06% -161.43%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$41.37K
YoY Change 43.06% -38.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -20.00K -29.65K
YoY Change -112.52%
NET CHANGE
Cash From Operating Activities -410.0K -422.5K
Cash From Investing Activities -10.00K -41.37K
Cash From Financing Activities -20.00K -29.65K
Net Change In Cash -440.0K -493.5K
YoY Change 34.13% 8.02%
FREE CASH FLOW
Cash From Operating Activities -$410.0K -$422.5K
Capital Expenditures $10.00K $41.37K
Free Cash Flow -$420.0K -$463.8K
YoY Change -11.37% 43.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Liabilities
Liabilities
1761794 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
652990 usd
CY2022Q1 crtg Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
17298 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0002
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
345000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
345000
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
69 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0002
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2627772 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001375195
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q4 us-gaap Cash
Cash
2356348 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
114201 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
314436 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
316992 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
378390 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1447358 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1414826 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
283175872
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
283175872
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
56633 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18136268 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17326992 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
865978 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
233348 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
320356 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
871458 usd
us-gaap Interest Expense
InterestExpense
106929 usd
us-gaap Interest Expense
InterestExpense
95442 usd
us-gaap Costs And Expenses
CostsAndExpenses
993267 usd
us-gaap Costs And Expenses
CostsAndExpenses
1287256 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
11588 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
946 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.002
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.004
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.005
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
255422376
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
272378123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
255905052
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1828320 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-507384 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1320936 usd
CY2023Q2 crtg Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
18087 usd
CY2023Q2 crtg Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1250 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-474295 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
865978 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3864151 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
70973 usd
CY2022Q1 crtg Stock Issued During Period Value Stock Options Exchanged For Common Shares
StockIssuedDuringPeriodValueStockOptionsExchangedForCommonShares
0 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-679341 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
3273081 usd
CY2022Q2 crtg Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
20567 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
18723 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-606969 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2705402 usd
us-gaap Net Income Loss
NetIncomeLoss
-981679 usd
us-gaap Net Income Loss
NetIncomeLoss
-1286310 usd
us-gaap Depreciation
Depreciation
4746 usd
us-gaap Depreciation
Depreciation
2223 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
41315 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
41315 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
32532 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
29349 usd
us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
89696 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-82722 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-62021 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-0 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-11793 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
15531 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
173981 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-804833 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-875932 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41374 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73282 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
61398 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1250 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-60148 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-906355 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-949214 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2356348 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4053327 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1449993 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3104113 usd
us-gaap Interest Paid Net
InterestPaidNet
68359 usd
us-gaap Interest Paid Net
InterestPaidNet
65196 usd
crtg Stock Options Exchanged For Common Stock
StockOptionsExchangedForCommonStock
0 usd
crtg Stock Options Exchanged For Common Stock
StockOptionsExchangedForCommonStock
180 usd
crtg Stock Issued To Settle Liabilities From Services Received
StockIssuedToSettleLiabilitiesFromServicesReceived
18087 usd
crtg Stock Issued To Settle Liabilities From Services Received
StockIssuedToSettleLiabilitiesFromServicesReceived
37865 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from the estimates and assumptions used.</p>
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
242442697
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
235713548
us-gaap Net Income Loss
NetIncomeLoss
-17326992 usd
CY2023Q2 crtg Working Capital Deficit
WorkingCapitalDeficit
1167036 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
61398 usd
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 usd
CY2023Q2 us-gaap Debt Current
DebtCurrent
0 usd
CY2022Q4 us-gaap Debt Current
DebtCurrent
61398 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1447358 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1414826 usd
crtg Amortization Associated With Commitment Fee
AmortizationAssociatedWithCommitmentFee
8674 usd
crtg Amortization Associated With Commitment Fee
AmortizationAssociatedWithCommitmentFee
6835 usd
CY2020Q2 crtg Share Exchange Agreement Number Of Options Authorized
ShareExchangeAgreementNumberOfOptionsAuthorized
21500000
CY2020Q2 crtg Share Exchange Agreement Exchange Ratio
ShareExchangeAgreementExchangeRatio
0.6 rate
crtg Share Based Compensation Arrangement By Share Based Payment Award Options Exchanged
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchanged
9500000
crtg Stock Issued During Period Shares Stock Options Exchanged For Common Shares
StockIssuedDuringPeriodSharesStockOptionsExchangedForCommonShares
5700000
CY2022 crtg Stock Issued During Period Shares Stock Options Exchanged For Common Shares
StockIssuedDuringPeriodSharesStockOptionsExchangedForCommonShares
5700000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
132514000
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0555
CY2022 crtg Class Of Warrant Or Right Contractual Term
ClassOfWarrantOrRightContractualTerm
P3Y7M17D
crtg Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
12500000
crtg Class Of Warrant Or Right Exercised During Period Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
0.0001
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
120014000
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0612
crtg Class Of Warrant Or Right Contractual Term
ClassOfWarrantOrRightContractualTerm
P3Y1M9D
CY2023Q2 crtg Class Of Warrant Or Right Intrinsic Value
ClassOfWarrantOrRightIntrinsicValue
509850 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
89696 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
77158160
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.070
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
77158160
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.070
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y2M19D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
77158160
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.070
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y2M19D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
77158160
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P3Y2M19D
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
77158160
us-gaap Operating Lease Expense
OperatingLeaseExpense
27300 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
15773 usd

Files In Submission

Name View Source Status
0001437749-23-023164-index-headers.html Edgar Link pending
0001437749-23-023164-index.html Edgar Link pending
0001437749-23-023164.txt Edgar Link pending
0001437749-23-023164-xbrl.zip Edgar Link pending
crtg-20230630.xsd Edgar Link pending
crtg-20230630_def.xml Edgar Link unprocessable
crtg-20230630_cal.xml Edgar Link unprocessable
crtg-20230630_lab.xml Edgar Link unprocessable
crtg-20230630_pre.xml Edgar Link unprocessable
crtg20230630_10q.htm Edgar Link pending
ex_555528.htm Edgar Link pending
ex_555529.htm Edgar Link pending
ex_555530.htm Edgar Link pending
ex_555531.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
crtg20230630_10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable